Compare Amgen, Inc. (AMGN) vs Dicks Sporting Goods Inc (DKS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Dicks Sporting Goods Inc — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Dicks Sporting Goods Inc trades at $217.98 (market cap $19.51B). The key difference: Amgen, Inc. is far larger — about 10.1× Dicks Sporting Goods Inc's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | DKS | |
|---|---|---|
Market Cap | $196.12B | $19.51B |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $239.17 |
52-Week Low | $271.18 | $187.78 |
Enterprise Value | $241.41B | $26.30B |
Dividend Yield | 2.77% | 2.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
DKS trades at $217.98, up 0.3% on the day, with a bearish technical signal but strong fundamentals including a 6% comps growth in Q1 2026 and three consecutive quarterly earnings beats. Recent developments include the launch of the ScoreCard+ loyalty program and a partnership with Lids to expand fan merchandise in over 100 stores by late summer 2026. The stock shows robust profitability with a 20.9% ROE and a 4.71% net income margin, supported by $1.17B net income in 2025.
The outlook is positive with a consensus price target of $261, representing 19.7% upside, and no sell ratings among 64 analysts. Key risks include ongoing shareholder litigation over fiduciary duties and competitive pressures in sporting goods retail. The stock presents a growth opportunity driven by strategic expansions and consistent earnings performance, though investors should monitor legal developments and market share sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Dicks Sporting Goods Inc
Dick's Sporting Goods is a leading omni-channel sporting goods retailer in the US It offers an extensive assortment of authentic sports equipment, apparel, footwear, and accessories through its stores and digital platforms.
Read more on DKS →
